REG - Ergomed plc - Change of auditor

ErgomedAnnouncement

16/07/2018 17:35

RNS Number : 8031U
Ergomed plc
16 July 2018
 


  PRESS RELEASE
 
                                                                                                    16 July 2018
 
Notification re Change of Auditors
 
Ergomed plc ("Ergomed" or the "Company")
 
At the Company's Annual General Meeting held on 12 June 2018, a resolution to appoint KPMG as Ergomed's auditors was proposed and approved by shareholders.
 
Ergomed now announces that on 13 July 2018 it wrote to shareholders explaining that, as planned, Deloitte LLP had resigned as auditor and KPMG had been appointed as the Company's new auditor. And as required by the Companies Act the Company also sent to shareholders a statement of Deloitte's reasons for their ceasing to hold office (namely that the directors of Ergomed have decided to appoint another firm as auditors).
 
This announcement is being made pursuant to the requirements of AIM Rule 20.
 
Enquiries:
 



Ergomed plc


   Tel: +44 (0) 1483 503 205




Stuart Jackson (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Michael Meade / Freddie Barnfield (Nominated Adviser)








James Black (Joint Broker)


















N+1 Singer


Tel: +44 (0) 20 7496 3000




Aubrey Powell (Joint Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott
Ivar Milligan / Olivia Manser


ergomed@consilium-comms.com














MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke













 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCEAKXKFAXPEFF